True VALUE of reducinq new-onset diabetes [5]

Hong Kong Medical Journal

Volumn 10, Issue 6, 2004, Pages 441-

  Chan, N N ^a  

^a Qualigenics Diabetes Centre   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; THIAZIDE DIURETIC AGENT; VALSARTAN; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; DIABETES MELLITUS; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LETTER; LONG TERM CARE; MAJOR CLINICAL STUDY; OBESITY; PROGNOSIS; BLOOD; CARDIOVASCULAR DISEASE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS;

EID: 10844225319     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Cheung BMY. Sartans for hypertension - implications of the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial. Hong Kong Med J 2004;10:359.
2. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
3. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963-9.
4. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia: A link between hypertension, obesity and glucose intolerance. J Clin Invest 1985;75:809-17.